微血流成像在肿瘤诊断中的应用:系统综述与Meta分析
SMI汇总敏感度0.84(95%CI 0.80-0.87)、特异度0.79(95%CI 0.74-0.84)、AUC 0.88;浅表器官组与腹部器官组AUC均为0.89。结论认为SMI相比CDFI具有较高敏感度和特异度,是有前景的新技术。
要点
- SMI鉴别良恶性肿瘤汇总AUC 0.88,敏感度0.84、特异度0.79。
- 浅表器官(以乳腺为主)与腹部器官亚组AUC均为0.89。
- SMI可显示瘤内微血管形态与分布,弥补CDFI对微血流检测的局限。
核心结论
- SMI相比常规CDFI在鉴别良恶性肿瘤方面表现出较高的敏感度和特异度,是有前景的临床新技术。
研究设计与样本
- 系统综述与诊断试验准确性Meta分析,检索Web of Science、PubMed、Cochrane Library和Embase至2025年2月26日。
- 采用QUADAS-2工具评价方法学质量,Meta-DiSc 1.4检验阈值效应,STATA进行异质性检验并计算汇总敏感度、特异度、似然比、DOR及SROC曲线。
关键影像表现/征象
- SMI利用自适应算法高分辨率显示瘤内微血管形态和分布,常规超声主要依赖形态学特征、病灶边界和血流模式。
- 部分肿瘤良恶性灰度特征重叠,且CDFI检测微血管血流存在局限。
诊断标准与关键数值
- SMI总体汇总敏感度0.84(95%CI 0.80-0.87)、特异度0.79(95%CI 0.74-0.84)、AUC 0.88。
- 浅表器官组SMI敏感度0.84(95%CI 0.79-0.88)、特异度0.79(95%CI 0.73-0.84)、AUC 0.89。
- 腹部器官组SMI敏感度0.83(95%CI 0.77-0.88)、特异度0.81(95%CI 0.71-0.88)、AUC 0.89。
临床应用与阅片要点
- 在乳腺等浅表器官及肾脏、肝脏肿瘤良恶性鉴别中,可考虑用SMI观察瘤内微血管形态与分布作为CDFI的补充。
- 判读时注意SMI敏感度0.84、特异度0.79并非完美,仍需结合灰阶形态学特征综合判断。
局限性
- 腹部器官相关研究样本量有限,需未来扩大样本量。
- SMI在不同类型病变中的具体性能尚待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Tumor angiogenesis is a hallmark of malignant transformation. Abnormal vascular structure and blood flow characteristics provide crucial information for differentiating benign from malignant lesions. Conventional ultrasound relies primarily on morphological features, lesion boundaries, and blood flow patterns. However, some tumors exhibit overlapping grayscale characteristics between benign and malignant types. Moreover, color Doppler flow imaging (CDFI) has limitations in detecting microvascular flow. Superb microvascular imaging (SMI) utilizes adaptive algorithms to display intratumoral microvascular morphology and distribution with high resolution, potentially improving early differentiation. This research therefore conducted a diagnostic test accuracy meta-analysis to systematically assess and compare the diagnostic performance of SMI against conventional CDFI for distinguishing benign from malignant tumors.
MATERIALS AND METHODS: An extensive literature retrieval was performed across the Web of Science, PubMed, Cochrane Library, and Embase up to February 26, 2025. The retrieval focused on studies using SMI and CDFI for diagnosing tumors across various organ systems. The Quality Assessment of Diagnostic Accuracy Studies-2 tool was employed to evaluate methodological quality. Review Manager 5.4 was used to generate quality assessment figures. Meta-DiSc 1.4 was used for threshold effect testing (Spearman correlation between sensitivity and 1-specificity). STATA software was then utilized for heterogeneity testing and to compute pooled sensitivity, negative likelihood ratio (LR-), specificity, diagnostic odds ratio (DOR), and positive likelihood ratio (LR+). Summary receiver operating characteristic (SROC) curves were constructed.
RESULTS: Twenty-eight studies were included: 22 focused on superficial organ tumors (17 breast, 5 other) and 6 on abdominal organ tumors (Five kidney, One liver). Pooled analysis showed that SMI yielded an overall sensitivity of 0.84 (95% CI: 0.80-0.87), a specificity of 0.79 (0.74-0.84), and an area under the curve (AUC) of 0.88. In the superficial organ group, SMI yielded a sensitivity of 0.84 (0.79-0.88), a specificity of 0.79 (0.73-0.84), and an AUC of 0.89. In the abdominal organ group, it yielded a sensitivity of 0.83 (0.77-0.88), a specificity of 0.81 (0.71-0.88), and an AUC of 0.89.
CONCLUSION: SMI demonstrates high specificity and sensitivity for differentiating benign from malignant tumors compared to conventional CDFI. It thus represents a promising novel imaging technique for clinical adoption. Future research should expand sample sizes for abdominal organs and investigate the specific performance of SMI across different lesion types.
引用
- Zhou D, Wang L, Dai W, et al. Application of Microflow Imaging in Neoplasm Diagnosis: A Systematic Review and Meta-analysis. Acad Radiol. 2026. PMID: 42034502. doi:10.1016/j.acra.2026.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。